I'll research HUM (Humana) before writing the preview. Let me gather recent earnings materials, guidance, and news.Let me read the most recent earnings materials and check for recent news and prior quarters.Now let me get recent news and stock price data ahead of the Q2 report.Let me check recent 8-K filings and press releases, plus search news differently.Let me read a few key news items most relevant to HUM's Q2 setup.I have what I need. Here's the earnings preview.
Humana heads into Q2 as a stock that has round-tripped from disaster to darling in six months. After collapsing from ~$264 in early January to a March low near $164, HUM has more than doubled to ~$389 — up roughly +47% YTD and ~+137% off the March trough. The rally has been powered by a sector-wide "moderating Medicare Advantage cost trend" narrative, capped by UnitedHealth's blowout Q2 and a mid-July Wells Fargo upgrade to Overweight. The bar has moved up materially, so this print is less about whether numbers are "fine" and more about whether management can validate the market's newfound optimism on cost trend, Stars recovery, and the path to the 2028 margin target.
| Item | Status going in |
|---|---|
| Stock (7/28) | ~$389; YTD +47%, off ~5% from the July 1 high of ~$409 |
| FY26 Adjusted EPS guide | "at least $9.00" (vs. $17.14 in FY25 — a Stars-driven trough year) |
| FY26 GAAP EPS guide | "at least $8.36" (cut from "$8.89" at Q1 on non-cash items) |
| FY26 Insurance benefit ratio guide | 92.75% ± 25 bps |
| FY26 individual MA membership | ~+25% growth |
| Q1 result | Adjusted EPS $10.31, benefit ratio 89.4% (slightly better than "just under 90%") |
| Q2 MLR guidance (from Q1 call) | "slightly above 91%" |
Two forces drove the round-trip:
January reset. HUM (and the whole managed-care group — UNH, CVS, ELV all fell in tandem on Jan 27) reset lower on a weak FY26 setup. The core problem: a Bonus Year 2026 Star Ratings headwind that is the explicit reason 2026 adjusted EPS guidance ("at least $9.00") is down so sharply from 2025's $17.14. Humana also lost its lawsuit challenging its 2025 Star Ratings (court ruled against it in October 2025; the company has appealed).
The recovery. The Q1 beat (April 29) and, more importantly, an industry-wide shift in sentiment toward stabilizing/moderating MA cost trends re-rated the group. UnitedHealth's July 16 report was the exclamation point — it posted a Q2 medical cost ratio of ~86.7% vs. ~88.5% expected and raised FY26 adjusted EPS guidance to $19.50–$20.00 — and explicitly lifted HUM and CVS shares. Days earlier, Wells Fargo upgraded HUM to Overweight, arguing moderating MA cost trends "significantly decrease earnings risk" and could drive meaningful margin progress next year.
Implication: expectations are now elevated. A simple "in line" quarter may not be enough; the market wants confirmation of the improving-trend thesis and, ideally, a guidance raise.
Historically, second-quarter claims experience is the first real read on whether the year's cost assumptions hold, and it is especially important this year given Humana's ~25% surge in individual MA membership (a large, less-seasoned cohort). Management guided Q2 Insurance MLR to "slightly above 91%" and has repeatedly said early indicators — risk scores, admits per thousand, pharmacy, and completing claims through April — were running "in line to better than" expectations for both new and existing members.
Watch for: - Actual benefit ratio vs. the ~91%+ guide, and whether FY26 benefit-ratio guidance (92.75% ± 25 bps) is affirmed, tightened, or improved. - New-member cohort commentary — the single biggest source of uncertainty this year. - IBNR/reserve posture. In Q1, IBNR was up ~35% vs. ~22% MA membership growth; management framed this as deliberate conservatism. Any reserve release/build language will shape how "clean" the beat is. UNH's strong MLR is a supportive read-through, but Humana's book is far more MA-concentrated, so it is not a perfect proxy.
On the Q1 call, management explicitly promised to "share more about our progress in the Q2 earnings call once the hybrid season is complete." This is the crux of the entire investment thesis: - The path back to top-quartile Stars for Bonus Year 2028 is what underwrites the return to a ≥3% MA margin by 2028 (the core Investor Day commitment). - Management pointed to the Stars compensation metric in the proxy as a positive "indicator," while cautioning they cannot know industry thresholds until October. They also flagged a strong early start on BY2029 Stars (running ~5% ahead of last year's gap-closure pace on key HEDIS metrics). - New wrinkle: After the Clover Health court decision, CMS voluntarily recalculated all 2026 star ratings, boosting bonuses for some large players (UNH, Aetna) with "no insurers losing money." Whether this changes Humana's BY2026 math at all is worth probing.
Any incremental confidence — or hedging — on the Stars trajectory will move the stock more than the EPS print.
MA bids were submitted in June, so management should give color on 2027 positioning. Key messages from Q1 to test for consistency: - Management said the gap between funding and medical cost trend is larger heading into 2027 bids than it was a year ago, and it will cut benefits to stay on the 2028 margin path. - Stated priorities, in order: (1) margin/2028 trajectory, (2) retention, (3) growth (a "distant third"). Expect explicit acknowledgment that they must show margin progress in 2027. - The offsetting positive: a firmer CMS rate notice (2027 rates ultimately boosted ~5% after an initial freeze) and more mature cost-transformation levers (outsourcing, centralization, early-retirement program completing end of Q2). - Watch for: any early signal on 2027 membership posture (likely flat-to-down given benefit cuts) and whether they lean into holding members ahead of the expected 2028 Stars/TBC tailwind.
Humana is a normalization story trading on trough (Stars-depressed) 2026 earnings — at ~$389 on "at least $9.00" of adjusted EPS, the market is clearly discounting the Investor Day promise of a ≥3% MA margin and restored earnings power by 2028, not this year's numbers. Given how far the stock has run and how bullish the group sentiment has become post-UNH, the risk/reward into the print is asymmetric: the setup rewards (a) a benefit-ratio beat/affirmation that validates moderating cost trend on the large new cohort, and (b) a genuinely confident Stars update now that the hybrid season is done. Conversely, any hint of cost-trend slippage in the new-member book, a hedged Stars message, or 2027 bid commentary implying steeper benefit cuts/margin pressure could trigger a sharp de-rating from these levels.
Three questions I'd want answered on the call: 1. Did the Q2 benefit ratio come in at/under the ~91%+ guide, and is the new-member cohort still tracking "in line to better"? 2. After the hybrid season, how confident is management in the BY2028 top-quartile Stars recovery — and did the CMS 2026 recalculation change anything? 3. On 2027 bids, how much benefit reduction is required to show margin progress, and what does that imply for membership retention?
Sources: Humana Q1 2026 earnings call transcript and press release (April 29, 2026); Humana FY26 guidance; Reuters (UnitedHealth Q2, July 16, 2026); Bloomberg (Wells Fargo upgrade, July 13, 2026); Axios (MA star-ratings recalculation/reform, July 27, 2026); Finnhub daily prices.
Note: I could not retrieve HUM-specific consensus estimates for the Q2 quarter from the tools available, so "beat/miss" framing is relative to the company's own guidance rather than Street consensus.